US Senator Criticizes FDA's Tobacco Policy, Calls for Action

Regulations by 2FIRSTS.ai

Jan.11.2024

US Senator Criticizes FDA's Tobacco Policy, Calls for Action

Dick Durbin, the majority whip in the US Senate, criticized the FDA's tobacco policy, urging the Biden administration to ban flavored cigarettes and cigars.

According to WEHT, Dick Durbin, the Majority Whip of the United States Senate, has criticized the tobacco policy of the U.S. Food and Drug Administration (FDA).

Senator Durbin stated that the FDA has failed to protect children from the harm caused by e-cigarettes, calling it "unacceptable." He called on the Biden administration to promptly implement a rule that prohibits the production and sale of menthol cigarettes and flavored cigars.

Deborah Bin expressed, "I went to the Senate today and said, 'We have had enough."

For the sake of our children, the FDA needs to take action... I believe it is now time for these flavored cigarettes to be phased out from the market on all levels.

Devin has repeatedly criticized the FDA for its belated review of pre-market tobacco applications (PMTA) for e-cigarette manufacturers, with a federal court deadline set for September 2021.

References:

[1] Senator Durbin slams FDA's tobacco policies

Also Read:

[1] Opposition to Statewide Ban on Flavored Tobacco Products in NYC

#North America #United States #Traditional tobacco #Legislation #FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.

Altria reported Q3 2025 net revenue of $6.072 billion, a 3.0% year-on-year decline. Adjusted EPS increased 3.6% to $1.45. The company expanded its share repurchase program to $2 billion and launched the on!PLUS nicotine pouch in Florida, North Carolina, and Texas.

Oct.31 by 2FIRSTS.ai

ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting

The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.

Nov.24 by 2FIRSTS.ai

AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping

As South Africa’s leading lifestyle vaping brand, AIRSCREAM is accelerating its regional growth strategy with the launch of its bold new initiative, “Trust ML, Not Puff.” The campaign calls for factual, millilitre (ml)-based transparency across the vaping industry, directly confronting misleading puff-count marketing practices and promoting clear, standardised information that reflects the true value and capacity of vaping products.

Nov.28

Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;

Altria director George Muñoz plans to retire post-2026 annual meeting, not seeking re-election. Annual meeting expected on May 14.